David Rubin to Adrenal Cortex Hormones
This is a "connection" page, showing publications David Rubin has written about Adrenal Cortex Hormones.
Connection Strength
1.935
-
Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
Score: 0.451
-
We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011 Jun; 9(6):456-7.
Score: 0.301
-
Appropriate Use and Complications of Corticosteroids in Inflammatory Bowel Disease: A Comprehensive Review. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2068-2082.
Score: 0.203
-
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 Nov; 169(6):1282-1293.
Score: 0.201
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
Score: 0.199
-
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. J Crohns Colitis. 2025 Mar 05; 19(3).
Score: 0.198
-
International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
Score: 0.158
-
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
Score: 0.129
-
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
Score: 0.047
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
Score: 0.046